Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Nasal Gel Clear all
Not listed Phase 3 Interventional

Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis

NCT03472144
View directory record Official record
Conditions
Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinusitis, Sphenoidal, Chronic Sinusitis - Frontoethmoidal, Nasal Polyps, Nasal Polyp - Posterior
Interventions
gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold

NCT03005067
View directory record Official record
Conditions
Common Cold
Interventions
Carbomer 980 (1146A), Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Prevention and Treatment of Nausea Associated With Motion Sickness

NCT03986905
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine Nasal Gel, Placebo
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT04139018
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Timolol Gel, Placebo Gel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 30, 2026, 7:25 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

NCT04272255
View directory record Official record
Conditions
Motion Sickness
Interventions
scopolamine HBr, Transdermal Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Sep 30, 2026, 7:25 PM EDT
Withdrawn Phase 2 Interventional

RCT of SPG Blocks for Post-dural Headache

NCT03560349
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Lidocaine HCl Gel 2%, placebo gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT04947423
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

NCT06673641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo Nasal Gel
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Sep 30, 2026, 7:25 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Natesto Testosterone Nasal Gel for Hypogonadal Men

NCT05484167
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Natesto Nasal Product, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 30, 2026, 7:25 PM EDT
Not listed Phase 3 Interventional

Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer

NCT00002659
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin-e therapeutic implant
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

NCT04184115
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebos
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 30, 2026, 7:25 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

NCT03920644
View directory record Official record
Conditions
Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions
Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
Drug
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Federal
Eligibility
18 Years to 59 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT05548270
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 30, 2026, 7:25 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05886660
View directory record Official record
Conditions
Motion Sickness, Space, Motion Sickness, Sea Sickness
Interventions
DPI-386 Nasal Gel, Placebo Nasal Gel
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

NCT00823901
View directory record Official record
Conditions
Rosacea
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

NCT03915470
View directory record Official record
Conditions
Staphylococcal Infections, Surgical Site Infection
Interventions
XF-73, Placebo
Drug
Lead sponsor
Destiny Pharma Plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Gainesville, Florida • Pocatello, Idaho • Des Moines, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 30, 2026, 7:25 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

NCT04219982
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop®
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Sep 30, 2026, 7:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

NCT01592214
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Anaheim, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Sep 30, 2026, 7:25 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Testosterone and Neural Function

NCT06130449
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Natesto testosterone intranasal gel, Ayr Saline Nasal Gel
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Sep 30, 2026, 7:25 PM EDT